Volume 2 Supplement 1

Abstracts of the 2nd European Symposium on Focused Ultrasound Therapy

Open Access

Non-invasive treatment of uterine fibroids using MR guided high intensity focused ultrasound: results on quality of life, non-perfused volume ratio and size reduction over 12 months

  • Federica Ciolina1,
  • Fabrizio Boni1,
  • Fulvio Zaccagna1,
  • Luca Bertaccini1,
  • Beatrice Cavallo Marincola1,
  • Vincenzo Noce1,
  • Carola Palla1,
  • Alessandro Napoli1 and
  • Carlo Catalano1
Journal of Therapeutic Ultrasound20142(Suppl 1):A18

DOI: 10.1186/2050-5736-2-S1-A18

Published: 10 December 2014

Purpose

To evaluate the efficacy of MR guided acoustic ablation in symptoms relief and volume reduction over time.

Materials and method

110 leiomyomas in 98 women (average age 39,3 years) were treated with MRI-guided focused ultrasound (MRgFUS). The treatment is carried out using the ablative properties of the HIFU system under 3T MRI guide. Symptoms (e.g. menorrhagia, pelvic pain) were scored using Severity Score (SS) and quality of life was determined using the UFS-QOL score. Pre-treatment measurementes of leiomyoma volume were obtained by MR images. Immediately after treatment, Non-perfused Volume (NPV) was calculated from T1-w contrast-enhanced MR sequences. The average volume of treated fibroids was 90.27 ± 90.4 mm3. Follow-up images were obtained at 3 and 12 months after treatment and served to determine leiomyoma shrinkage. Qualitative and quantitative relations between fibroid volume, NPV ratio at treatment, and 12-month shrinkage were measured.

Results

MRgFUS treated patients demonstrated a significant change in USF-QoL score: mean SS score values were 48.6 ± 13.4 (pre-treatment), 25.1 ± 8.9 (three-months follow-up) and 19,3± 6.8 (twelve-months follow-up). Fibroids volume changed from 90.27±90.4 mm3 (before treatment) to 54 ± 66.1 mm3 (at 12 months follow up). We encountered a statistically significant difference between the two values (p = 0.001). Mean post-treatment VNP was 57,65±52.9 mm3, about 63% of total fibroid volume (p=0.001).

Conclusion

MRgFUS therapy of leyomioma results in a significant relief of symptoms and greater than 50% total fibroid ablation. The procedure is carried out in a totally non-invasive manner and features a high safety profile.

Authors’ Affiliations

(1)
Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome

Copyright

© Ciolina et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement